Breaking News


Effects of combined topical calcipotriol and etanercept in partial responders with psoriasis vulgaris and psoriatic arthritis


The efficacy of adjunctive topical calcipotriol 0.005% cream was evaluated in psoriasis vulgaris (PV) and psoriatic arthritis (PsA) patients partially responsive to etanercept. One hundred and twenty patients (mean age 48 years) with PV and PsA were enrolled. A 50-mg s.c. etanercept dose was administered twice weekly for 12 weeks, followed by 25 mg s.c. twice weekly for 12 weeks. At week 12, 45 patients did not achieve a Psoriasis Area and Severity Index decrease of at least 50% from baseline (PASI-50) and were administered calcipotriol cream twice daily for 4 weeks, then once daily for 8 weeks, together with etanercept. At week 24, of the 45 patients in the ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list